Henlius Presents P-III Data of HLX04 (biosimilar, bevacizumab) at CSCO 2020

Shots:

• The P-III HLX04-mCRC03 study involve assessing of HLX04 (7.5mg/kg, q3w, when combined with XELOX or 5mg/kg, q2w when combined with mFOLFOX6) vs reference bevacizumab + CT (XELOX or mFOLFOX6) as a 1L treatment in 675 patients in a ratio (1:1) with mCRC
• Results: PFSR36wk  (46.4% vs 50.7%); no difference in 2EPs including OS, PFS, ORR, TTR and DoR
• HLX04 is a bevacizumab biosimilar, indicated for advanced, metastatic, or recurrent NSCLC and metastatic colorectal cancer. Additionally, NMPA has accepted NDA of HLX04

Click here ­to­ read full press release/ article | Ref: Henlius | Image: Henlius